Ahmad Halwani

TL;DR: Nivolumab had substantial therapeutic activity and an acceptable safety profile in patients with previously heavily treated relapsed or refractory Hodgkin's lymphoma.

TL;DR: Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas and PD-L1/PD-L2 locus integrity and protein expression.

TL;DR: HSCT after PD-1 blockade appears feasible with a low rate of relapse, however, there may be an increased risk of early immune toxicity, which could reflect long-lasting immune alterations triggered by prior PD- 1 blockade.

TL;DR: Findings indicate that polymorphisms in the C1qA gene may affect the clinical response and duration of response to rituximab therapy of follicular lymphoma and could have direct implications on designing antibodies with improved efficiency.

TL;DR: Nivolumab, a fully human IgG4 monoclonal PD-1 receptor blocking antibody, potentiates T cell activity, and has clinical efficacy in various solid tumors is enrolled in patients with relapsed or refractory lymphoid malignancies and key secondary endpoints included anti-tumor activity and expression of immunomodulatory proteins in tumor biopsies.